

30.01.2022

13:30 - 15:30 AI in sarcoma - Part 1 **AIDA**

Moderation: P.G. Casali¹, R. Jones², ¹Milan/IT, ²London/GB

13:30 - 13:50 **In a nutshell: What is AI?**

P. Huang, London/GB

13:50 - 14:05 **Big (FAIR) data in sarcoma to predict prognosis: perSARC**

M. Van De Sande, Leiden/NL

14:05 - 14:20 **Big (FAIR) data in sarcoma to predict prognosis: SARCulator**

D. Callegaro, Milan/IT

14:20 - 14:40 **Radiomics in sarcoma: Where do we stand?**

M. Blackledge, London/GB

14:40 - 15:00 **AI and digital sarcoma pathology: Where do we stand?**

A.P. Dei Tos, Padova/IT

15:00 - 15:30 **Discussion**

16:00 - 17:30 AI in sarcoma - Part 2 **AIDA**

Moderation: J.-Y. Blay¹, J. Bovée², ¹Lyon/FR, ²Leiden/NL

16:00 - 16:20 **From WGS identification of “actionable” targets to clinical benefit: How to improve?**

A. Wagner, Boston/US

16:20 - 16:40 **In silico prediction of drug response in sarcoma**

D. Van Ijzendoorn, Stanford/US

16:40 - 17:00 **AI in sarcoma: How to move forward to support clinical decision making?**

R. Maki, Philadelphia/US

17:00 - 17:30 **Discussion**

31.01.2022

08:30 - 10:00 Paediatric / AYA sarcomas **AIDA**
Moderation: J. Bovée¹, B. Hassan², M. Van De Sande¹, ¹Leiden/NL, ²Oxford/GB

08:30 - 09:00 **Case presentation 1 and discussion**
U. Dirksen, Essen/DE

09:00 - 09:30 **Case presentation 2 and discussion**
B. Kasper, Mannheim/DE

09:30 - 10:00 **Case presentation 3 and discussion**
K. Janeway, Boston/US

08:30 - 10:00 Management of local disease **Norma**
Moderation: E. Baldini¹, P. Hohenberger², ¹Boston/US, ²Mannheim/DE

08:30 - 08:45 **The pathology of STS and GIST**
M. Sbaraglia, Treviso/IT

08:45 - 09:00 **The pathology of bone sarcomas**
S. Wai Lam, Leiden/NL

09:00 - 09:15 **The genetics of GIST**
E. Wardelmann, Muenster/DE

09:15 - 09:30 **Surgical margins in sarcomas and GIST**
M. Smith, London/GB

09:30 - 09:45 **Principles of radiation therapy in STS**
A. Miah, London/GB

09:45 - 10:00 **Discussion**

10:00 - 10:30 Coffee break **Roses restaurant**

10:30 - 12:00	GIST	AIDA
	Moderation: S. Bauer ¹ , J.T. Trent ² , E. Wardelmann ³ , ¹ Essen/DE, ² Miami/US, ³ Muenster/DE	
10:30 - 11:00	Case presentation 1 and discussion <u>A. Gronchi</u> , Milan/IT	
11:00 - 11:30	Case presentation 2 and discussion <u>S. Patel</u> , Houston/US	
11:30 - 12:00	Case presentation 3 and discussion <u>C. Raut</u> , Boston/US	
10:30 - 12:00	Management of advanced disease	Norma
	Moderation: B. Kasper ¹ , R. Maki ² , ¹ Mannheim/DE, ² Philadelphia/US	
10:30 - 10:45	Principles of systemic therapy for sarcomas <u>M. Ahlström</u> , Lund/SE	
10:45 - 11:00	Targeted therapy for GIST <u>A. Le Cesne</u> , Villejuif/FR	
11:00 - 11:15	Immunotherapy for STS <u>C.M. Valverde Morales</u> , Barcelona/ES	
11:15 - 11:30	The value of WGS to search for therapeutic targets <u>R. Maestro</u> , Aviano/IT	
11:30 - 11:45	Local therapy for metastatic disease <u>A. Hayes</u> , London/GB	
11:45 - 12:00	Discussion	
12:00 - 13:00	Lunch	Roses restaurant
13:00 - 13:10	ESMO Sarcoma & GIST 2022 Opening	AIDA
	Moderation: J. Bovée ¹ , R. Jones ² , ¹ Leiden/NL, ² London/GB	
13:00 - 13:10	ESMO Sarcoma & GIST 2022 Welcome <u>J. Bovée</u> ¹ , <u>R. Jones</u> ² , ¹ Leiden/NL, ² London/GB	

13:10 - 14:10 Collaborative session - SPAEN AIDA

13:10 - 14:10 **To be announced**

14:15 - 15:45 STS 1 AIDA

Moderation: J. Bovée¹, R. Jones², ¹Leiden/NL, ²London/GB

14:15 - 14:30 **Update on STS pathology: WHO, WGS, ICCR and more....**

C. Fletcher, Boston/US

14:30 - 14:45 **Is doxorubicin still the standard 1st line therapy for all sarcoma subtypes?**

P. Reichardt, Berlin/DE

14:45 - 15:00 **Ultrarare STS: How do we make progress?**

A.M. Frezza, Milan/IT

15:00 - 15:15 **Clinical trials for rare STS: How to learn the most from it**

P. Schoeffski, Leuven/BE

15:15 - 15:30 **How to approach the surgical margin across STS subtypes**

P. Rutkowski, Warsaw/PL

15:30 - 15:45 **Discussion**

15:45 - 16:15 Coffee break Roses restaurant



16:15 - 17:45	GIST	AIDA
	Moderation: G. Demetri ¹ , A. Gronchi ² , ¹ Boston/US, ² Milan/IT	
16:15 - 16:30	Pathology and molecular assessment of GIST: Implications for risk stratification <u>J.A. Fletcher</u> , Boston/US	
16:30 - 16:45	Improvement on local treatment: Use of image guided surgery <u>Y. Schrage</u> , Leiden/NL	
16:45 - 17:00	Update on medical therapy <u>J.T. Trent</u> , Miami/US	
17:00 - 17:15	Preclinical leads for novel therapeutic approaches <u>S. Bauer</u> , Essen/DE	
17:15 - 17:30	How to implement liquid biopsies in clinical trials <u>C. Serrano</u> , Barcelona/ES	
17:30 - 17:45	Discussion	

01.02.2022

08:30 - 10:00 STS 2 **AIDA**
 Moderation: A.M. Frezza¹, A. Hayes², ¹Milan/IT, ²London/GB

08:30 - 08:45 **The requirements of good surgery for STS, today**
S. Bonvalot, Paris/FR

08:45 - 09:00 **On the use of neoadjuvant chemotherapy: Pro's**
A. Gronchi, Milan/IT

09:00 - 09:15 **On the use of neoadjuvant chemotherapy: Con's**
A. Le Cesne, Villejuif/FR

09:15 - 09:30 **The management of residual disease after TKIs in GIST**
C. Swallow, Toronto/CA

09:30 - 09:45 **Radiotherapy: Can we do better with less?**
R.L. Haas, Amsterdam/NL

09:45 - 10:00 **Discussion**

10:30 - 12:00	Bone tumours	AIDA
	Moderation: S. Bielack ¹ , S. Strauss ² , ¹ Stuttgart/DE, ² London/GB	
10:30 - 10:45	Bone sarcoma differential diagnosis: Methylation array versus morphology <u>D. Baumhoer</u> , Basel/CH	
10:45 - 11:00	Ultrarare bone cancers: How do we make progress? <u>E. Palmerini</u> , Bologna/IT	
11:00 - 11:15	Update on chordoma <u>S. Stacchiotti</u> , Milan/IT	
11:15 - 11:30	Proton therapy for chordoma and chondrosarcoma <u>B. Timmermann</u> , Essen/DE	
11:30 - 11:45	The risks versus benefits of denosumab for GCTB <u>H. Gelderblom</u> , Leiden/NL	
11:45 - 12:00	Discussion	
12:00 - 12:50	Lunch	Roses restaurant
12:50 - 14:05	Deciphera Pharmaceuticals - Mutations and multi-modality treatment in patients with advanced GIST	AIDA
12:50 - 12:55	Introduction <u>H. Gelderblom</u> , Leiden/NL	
12:55 - 13:15	Role of surgery in patients with advanced GIST <u>A. Gronchi</u> , Milan/IT	
13:15 - 13:35	GIST: Do mutations matter, and when? <u>C. Serrano</u> , Barcelona/ES	
13:35 - 13:55	Advanced GIST: Treatment or management? <u>A. Le Cesne</u> , Villejuif/FR	
13:55 - 14:05	Live Q&A and discussion	

14:15 - 15:45	Immunotherapy in sarcomas	AIDA
	Moderation: J.-Y. Blay ¹ , P. Reichardt ² , ¹ Lyon/FR, ² Berlin/DE	
14:15 - 14:35	Search for predictive biomarkers: TMB, MMR and PDL1	
	<u>W.D. Tap</u> , New York/US	
14:35 - 14:55	Search for predictive biomarkers: Sarcoma immunoscore	
	<u>J. Martin Broto</u> , Seville/ES	
14:55 - 15:15	Immunotherapy for sarcomas: What have we learned so far?	
	<u>R. Maki</u> , Philadelphia/US	
15:15 - 15:35	Immunotherapy for sarcomas: Combination strategies	
	<u>A. Napolitano</u> , London/GB	
15:35 - 15:45	Discussion	
15:45 - 16:15	Coffee break	Roses restaurant
16:15 - 17:45	Gynaecological/visceral sarcomas	AIDA
	Moderation: R.L. Haas ¹ , C. Swallow ² , ¹ Amsterdam/NL, ² Toronto/CA	
16:15 - 16:35	What's new in WHO for gynaecological sarcomas	
	<u>A.P. Dei Tos</u> , Padova/IT	
16:35 - 16:55	Visceral sarcomas: Treat the same as other STS? RT view	
	<u>E. Baldini</u> , Boston/US	
16:55 - 17:15	Gynaecological sarcomas: Treat the same as other STS?	
	<u>S. George</u> , Boston/US	
17:15 - 17:35	Visceral sarcoma: Treat the same as other STS? Surgical view	
	<u>P. Hohenberger</u> , Mannheim/DE	
17:35 - 17:45	Discussion	

02.02.2022

08:30 - 10:00 Novel therapeutic approaches **AIDA**
Moderation: P.G. Casali¹, W.D. Tap², ¹Milan/IT, ²New York/US

08:30 - 08:45 **Brachyury vaccination strategies for chordoma**
A. Wagner, Boston/US

08:45 - 09:00 **CAR-T cell / NY-ESO1 for synovial sarcoma**
G. Demetri, Boston/US

09:00 - 09:15 **WGS based tumour agnostic therapy: Where do we stand?**
A. Dufresne, Lyon/FR

09:15 - 09:30 **The use of AI in sarcoma care**
D. Van Ijzendoorn, Stanford/US

09:30 - 09:45 **Individualised therapy for STS: On the use of an app**
M. Van De Sande, Leiden/NL

09:45 - 10:00 **Discussion**

10:00 - 10:30 Coffee break **Roses restaurant**

10:30 - 12:00	Paediatric / AYA sarcomas Moderation: A.P. Dei Tos ¹ , M. Ahlstrom ² , ¹ Padova/IT, ² Lund/SE	AIDA
10:30 - 10:45	Round cell sarcomas: Should we split or should we lump? <u>S. Strauss</u> , London/GB	
10:45 - 11:00	Impact of age on patient quality of life <u>W. Van Der Graaf</u> , Amsterdam/NL	
11:00 - 11:15	Impact of age on radiotherapy <u>A. Miah</u> , London/GB	
11:15 - 11:30	Osteosarcoma: Where do we go from here? <u>S. Bielack</u> , Stuttgart/DE	
11:30 - 11:45	Paediatric GIST: What makes it so different? <u>L. Helman</u> , Dallas/US	
11:45 - 12:00	Discussion	
12:00 - 12:50	Lunch	Roses restaurant
12:50 - 14:05	Industry satellite symposium 2	AIDA
12:50 - 14:05	To be announced	

14:15 - 15:45	Update on clinical research in sarcoma field	AIDA
	Moderation: R. Maki ¹ , A. Wagner ² , ¹ Philadelphia/US, ² Boston/US	
14:15 - 14:30	Radiomics for sarcomas <u>M. Blackledge</u> , London/GB	
14:30 - 14:45	Update on novel statistical designs for rare cancer trials: What have we learned so far? <u>B. Hassan</u> , Oxford/GB	
14:45 - 15:00	What level of evidence do we need for drug approval in rare cancers? <u>P.G. Casali</u> , Milan/IT	
15:00 - 15:15	Lessons from the NET-SARC consortium <u>J.-Y. Blay</u> , Lyon/FR	
15:15 - 15:30	Proteomics in sarcomas: How to identify new biomarkers? <u>P. Huang</u> , London/GB	
15:30 - 15:45	Discussion	
15:45 - 15:55	Closing & take home messages	AIDA
	Moderation: J. Bovée ¹ , R. Jones ² , ¹ Leiden/NL, ² London/GB	